Astrazeneca Launches Three R&D Initiatives In China

With the creation of two new research centres and a billion-dollar fund in China, AstraZeneca looks set to make waves in biomedical research and healthcare in Asia.

AstraZeneca’s Lung Cancer Drug Receives Regulatory Approval In China

Tagrisso, a small molecule inhibitor drug, has been approved in China as a first-line treatment for patients with non-small cell lung tumors bearing specific mutations.

AstraZeneca Expands Presence in Asia With Deals in China and Japan

AstraZeneca has entered a strategic alliance with WuXi AppTech and acquired Takeda's respiratory business.

Tianjin & AstraZeneca Collaborate On Cardiovascular Disease

Tianjin Medical University and Astrazeneca will collaborate to develop soluble epoxide hydrolase inhibitors for the treatment of cardiac fibrosis.

AstraZeneca, Shenzhen Uni To Study Chronic Kidney Disease

AstraZeneca and Shenzhen University Health Science Center will conduct pre-clinical research on chronic kidney disease, a large and growing unmet medical need in China.

Drug-Resistant Bugs Surge During Pilgrimage Season

Scientists have detected a 20-fold increase in drug-resistant bacteria in South Asian waters during pilgrimage season.

AstraZeneca Partners Korean Government In Cancer Program

Under the proposed program, Korean scientists will gain grants and priority access to AstraZeneca compounds for testing.

A*STAR, AstraZeneca To Develop Gram-Negative Antibacterials

A*STAR has signed an agreement with biopharmaceutical company AstraZeneca to develop new drugs to treat gram-negative bacterial infections.

Ironwood, AstraZeneca Initiate Linaclotide PhIII Trial In China

Ironwood and AstraZeneca have initiated a Phase III clinical trial of linaclotide for the treatment of adults with irritable bowel syndrome with constipation.

AstraZeneca, Fudan University To Collaborate In China

AstraZeneca and Fudan University are set to collaborate on cardiovascular research in China.